AgingResearch.NewsJoin free

Haya Therapeutics

CompanySwitzerland

Haya Therapeutics develops one asset, in phase 1 (HTX-001 in nonobstructive hypertrophic cardiomyopathy). Mostly oligonucleotide acting on WISPER; based in Switzerland.

1
Asset
Furthest stage
Phase 1
1
Trial
2
Signals

Pipeline

1

  • HTX-001

    Antisense oligonucleotide targeting WISPER long noncoding RNA to reduce cardiac fibrosis.

    Phase 1, Oligonucleotide, WISPER, nonobstructive hypertrophic cardiomyopathy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Signals2

Intelligence